Robert L. Danner Jr., M.D.

Senior Investigator

Critical Care Medicine Department

NIH Clinical Center

Building 10, Room 2C145
10 Center Drive
Bethesda, MD 20892

301-496-9320

rdanner@nih.gov

Research Topics

Septic shock and multiple organ failure are long-term research interests of Dr. Danner's section. Recent investigations have focused on nitric oxide and carbon monoxide as endogenous regulators of inflammation, nuclear receptor signaling as a means for targeting vascular inflammation in acute and chronic conditions, such as sepsis and pulmonary arterial hypertension, respectively, and the functional genomics of critical illness and injury. Dr. Danner directs the Functional Genomics Facility in the Critical Care Medicine Department at the NIH Clinical Center.

Biography

Dr. Danner received his undergraduate degree in biology from Johns Hopkins University and his degree in medicine from Cornell University. He completed residency training in internal medicine at New York Hospital/Cornell University Medical Center, and his fellowship training in critical care medicine and infectious diseases at NIH. Dr. Danner heads the Infectious Diseases Section and Continuous Renal Replacement Therapy Service of the Critical Care Medicine Department at the NIH Clinical Center. He became a Senior Investigator at NIH in 1988 and holds the rank of Clinical Professor of Medicine at Georgetown University Medical Center.

Dr. Danner served as a member of the Anti-Infective Drug Products Advisory Committee of the Food and Drug Administration. He has been a member of the Editorial Advisory Board of Journal of Infectious Diseases, the Editorial Board of Critical Care Medicine, and the Society of Critical Care Medicine's Continuing Education Committee. As Chair of the Critical Care Medicine Test Committee and former Director on the American Board of Internal Medicine (ABIM), Dr. Danner oversaw the transition of Critical Care Medicine from a certificate of "Added Qualification" to recognition as a full-fledged subspecialty Board of the ABIM.

Selected Publications

  1. Awad KS, Elinoff JM, Wang S, Gairhe S, Ferreyra GA, Cai R, Sun J, Solomon MA, Danner RL. Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2016;310(2):L187-201.

  2. Dougherty EJ, Elinoff JM, Ferreyra GA, Hou A, Cai R, Sun J, Blaine KP, Wang S, Danner RL. Mineralocorticoid Receptor (MR) trans-Activation of Inflammatory AP-1 Signaling: DEPENDENCE ON DNA SEQUENCE, MR CONFORMATION, AND AP-1 FAMILY MEMBER EXPRESSION. J Biol Chem. 2016;291(45):23628-23644.

  3. Cortés-Puch I, Hicks CW, Sun J, Solomon SB, Eichacker PQ, Sweeney DA, Nieman LK, Whitley EM, Behrend EN, Natanson C, Danner RL. Hypothalamic-pituitary-adrenal axis in lethal canine Staphylococcus aureus pneumonia. Am J Physiol Endocrinol Metab. 2014;307(11):E994-E1008.

  4. Wang S, Awad KS, Elinoff JM, Dougherty EJ, Ferreyra GA, Wang JY, Cai R, Sun J, Ptasinska A, Danner RL. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY. J Biol Chem. 2015;290(32):19544-57.

  5. Wang S, Dougherty EJ, Danner RL. PPARγ signaling and emerging opportunities for improved therapeutics. Pharmacol Res. 2016;111:76-85.


This page was last updated on August 21st, 2017